Adults 40 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Berg Balance ScalePrimary· 9 weeks
Efficacy was measured as a change on the Berg Balance Scale (BBS) from baseline to the end of the study after 8 weeks on drug. The BBS is a 14-item measure consisting of basic balance tasks, with a final score indicative of overall balance ability. The maximum score is 56 and minimum is 0. Higher scores reflect better balance.
Baseline
Group
Value
95% CI
Varenicline
43.93
± 1.97
Sugar Pill
41.14
± 2.55
End Point
Group
Value
95% CI
Varenicline
43.25
± 1.84
Sugar Pill
45.13
± 2.34
Frontal Assessment BatterySecondary· 9 weeks
The change in cognitive functioning was measured with the Frontal Assessment Battery (FAB, score range 0-18) and the Mini-Mental State Exam (MMSE, score range 0-30) from baseline to 8 weeks on drug. High scores on both scales indicate better performance. The FAB measures executive functioning and consists of the following 6 sections: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy.
Baseline
Group
Value
95% CI
Varenicline
17.40
± 0.97
Sugar Pill
15.25
± 2.77
End point
Group
Value
95% CI
Varenicline
17.70
± 2.16
Sugar Pill
15.19
± 2.74
Mini Mental Status Exam (MMSE)Secondary· 9 weeks
The change in cognitive functioning was measured with the Mini-Mental State Exam (MMSE) from baseline to 8 weeks on drug. The maximum score on the MMSE is 30 and lowest score 0, with higher score indicating better cognitive function.
Baseline
Group
Value
95% CI
Varenicline
29.08
± 1.17
Sugar Pill
28.19
± 1.72
End point
Group
Value
95% CI
Varenicline
28.00
± 2.00
Sugar Pill
28.13
± 1.7
Sponsor's own description
The purpose of this study is to determine if varenicline is effective in improving gait and balance impairment in patients with Parkinson disease.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06029907 — Project HOPES: Healthy Options for Pain and Ending Smoking. A Program for Cancer Survivors.
· Phase 4
· completed
NCT06218823 — Tobacco Treatment Comparison for Cancer Care
· Phase 4
· completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Rush University Medical Center trials
Trials by the same sponsor.
NCT07278076 — Clinical Decision-Making During FEES: The Impact of Residue Amount and Location
· NA
· not yet recruiting
NCT07088120 — PRECISION-CPR: PRecision-Controlled Ventilation in CPR
· NA
· not yet recruiting
NCT06894719 — Oral Tranexamic Acid After Total Knee Arthroplasty
· Phase 4
· not yet recruiting
NCT06229392 — A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
· Phase 1
· withdrawn
NCT07452406 — Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rush University Medical Center
Last refreshed: 30 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01341080.